ABVC BioPharma, Inc.
ABVC
$0.742
-$0.1725-18.86%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 224.51% | 9,658.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 232.45% | 9,658.33% | |||
| Cost of Revenue | 50.00% | -33.33% | |||
| Gross Profit | 232.48% | 12,900.00% | |||
| SG&A Expenses | -71.40% | -68.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -70.52% | -68.26% | |||
| Operating Income | 106.84% | 71.65% | |||
| Income Before Tax | 90.32% | 65.24% | |||
| Income Tax Expenses | 100.36% | -- | |||
| Earnings from Continuing Operations | 89.45% | 68.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -120.12% | 441.67% | |||
| Net Income | 81.57% | 74.25% | |||
| EBIT | 106.84% | 71.65% | |||
| EBITDA | 107.66% | 72.02% | |||
| EPS Basic | 83.22% | 77.87% | |||
| Normalized Basic EPS | 79.40% | 78.69% | |||
| EPS Diluted | 77.78% | 77.72% | |||
| Normalized Diluted EPS | 79.40% | 78.69% | |||
| Average Basic Shares Outstanding | 9.57% | 16.28% | |||
| Average Diluted Shares Outstanding | 9.57% | 16.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
